

# INPLASY

## The role of adjuvant radiotherapy after surgery in early-stage tongue carcinoma. A systematic review and meta-analysis

INPLASY2023120042

doi: 10.37766/inplasy2023.12.0042

Received: 10 December 2023

Published: 10 December 2023

Yuan, SW<sup>1</sup>; Li, LT<sup>2</sup>.

### Corresponding author:

Shiwang Yuan

2521599684@qq.com

### Author Affiliation:

The Affiliated Hospital of Xuzhou Medical University.

### ADMINISTRATIVE INFORMATION

**Support** - The Affiliated Hospital of Xuzhou Medical University.

**Review Stage at time of this submission** - Preliminary searches.

**Conflicts of interest** - None declared.

**INPLASY registration number:** INPLASY2023120042

**Amendments** - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 10 December 2023 and was last updated on 10 December 2023.

### INTRODUCTION

**Review question / Objective** The role of adjuvant radiotherapy after surgery in early-stage tongue carcinoma.

**Condition being studied** Our study patients were diagnosed with oral tongue cancer and we focused on the role of radiotherapy of early-stage (T1-2N0M0) patients after surgery.

### METHODS

**Search strategy** We use the four databases of PubMed, Cochrane Library, Web of Science and Chinese databases, a systematic literature search was conducted in October, 2023.

**Participant or population** The study included patients who had been diagnosed with oral tongue cancer. In order to study the role of radiotherapy of

early-stage (T1-2N0) patients after surgery. The eligible studies should meet the following criteria: (1) Tongue cancer confirmed by pathological diagnosis; (2) The stage of patients were T1-2N0M0; (3) Providing survival data, including hazard ratio (HR) and 95% confidence interval (CI) measurements for OS, RFS, DFS or PFS, or providing Kaplan-Meier curves based on post-operative radiotherapy (PORT) and surgery only. The following studies have been excluded from consideration due to the following reasons: (1) Comment, animal studies, conference abstract, none-comparative studies, letter, editorials, reviews and meta-analysis; (2) Studies without available data can be extracted.

**Intervention** Patients with oral tongue cancers undergoing post-operative radiotherapy (PORT).

**Comparator** Patients with oral tongue cancers undergoing no treatment after surgery.

---

**Study designs to be included** Retrospective studies or randomized controlled trials.

**Eligibility criteria** (1) Tongue cancer confirmed by pathological diagnosis; (2) The stage of patients was T1-2N0M0; (3) Providing survival data, including hazard ratio (HR) and 95% confidence interval (CI) measurements for OS, RFS, DFS or PFS, or providing Kaplan-Meier curves based on post-operative radiotherapy (PORT) and surgery only.

**Information sources** We use the four databases of PubMed, Cochrane Library and Web of Science and Chinese databases, a systematic literature search was conducted in October, 2023.

**Main outcome(s)** Survival data, including hazard ratio (HR) and 95% confidence interval (CI) measurements for OS, LRFS, DFS or PFS.

**Quality assessment / Risk of bias analysis** Quality assessment was performed using the Newcastle–Ottawa quality assessment scale (NOS) or The Cochrane ROB. NOS criteria scores range from 0 (lowest) to 9 (highest), and a NOS score  $\geq 6$  is considered a high-quality study.

**Strategy of data synthesis** The statistical analysis was performed using Stata 15.0. It involved calculating the correlations between treatment measures and OS, RFS, PFS, or DFS. If  $P < 0.05$  and  $I^2 > 50\%$ , it indicated high heterogeneity, and a random-effects model was applied. Otherwise, a fixed-effects model was used. Additionally, a sensitivity analysis was conducted by systematically excluding individual studies in order to evaluate the robustness of the meta-analysis.  $P < 0.05$  was considered statistically significant.

**Subgroup analysis** None.

**Sensitivity analysis** None.

**Country(ies) involved** China.

**Keywords** PORT, early stage, tongue cancer.

#### **Contributions of each author**

Author 1 - Shiwang Yuan.

Email: 2521599684@qq.com

Author 2 - Liantao Li.

Email: liliantao@xzhmu.edu.cn